|
|
|
(State or other jurisdiction
of incorporation) |
(Commission
File Number) |
(IRS Employer
Identification No.) |
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading
Symbol(s) |
Name of each exchange
on which registered |
par value NIS0.01 per share |
|
The
|
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
UROGEN PHARMA LTD.
|
|||
Date: September 12, 2022
|
By:
|
/s/ Don Kim
|
|
Don Kim
|
|||
Chief Financial Officer
|
Document And Entity Information |
Sep. 08, 2022 |
---|---|
Document Information [Line Items] | |
Entity, Registrant Name | UROGEN PHARMA LTD. |
Document, Type | 8-K |
Document, Period End Date | Sep. 08, 2022 |
Entity, Incorporation, State or Country Code | L3 |
Entity, File Number | 001-38079 |
Entity, Tax Identification Number | 98-1460746 |
Entity, Address, Address Line One | 400 Alexander Park Drive, 4th Floor |
Entity, Address, City or Town | Princeton |
Entity, Address, State or Province | NJ |
Entity, Address, Postal Zip Code | 08540 |
City Area Code | 646 |
Local Phone Number | 768-9780 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Ordinary Shares |
Trading Symbol | URGN |
Security Exchange Name | NASDAQ |
Entity, Emerging Growth Company | false |
Amendment Flag | false |
Entity, Central Index Key | 0001668243 |
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end
0!5+@7 SKF_KQ&?O\Z#56]Q\=,DG-V0[KAF ;F99U, MJ.>!VM>(S0-BYQT>U G,B@Q%C="I"NL@%8]?QR-Y7$Y\"IT">+) NVHC[0:@OEBQ-N5AH6+"Y+F>9P^ ALIQR7+HY5"%E"ST-"U$F)!8 M(:6+!5!;^/TNJ;Y)NU@QB/K2B)P*V)!^O*:"TT"!CH"OX==Q=(OZ?!C47! , M$_4Q%4,>U,#H2/P7&^<:O_\ZHW;=$+&9!K)*!$F:
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